Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia

<i>Background:</i> Biosimilars are safe and effective treatments for chronic diseases, including cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) oversees the quality and registration of biosimilars in Saudi Arabia. However, disparities among regulatory authorities such as the lack of guidelines for biosimilars in rheumatology affect healthcare providers' perceptions, leading to hesitancy in switching from reference products to biosimilars. This study aimed to explore the perceptions of Saudi healthcare professionals regarding biosimilars. <i>Methods:</i> A convenience sample of 87 participants (75 pharmacists and 12 physicians) was analyzed. The data were collected between December 2022 and February 2023. A logistic regression model was used to predict the intention toward biosimilars. <i>Results:</i> Years of practice among physicians significantly influenced their intention to prescribe biosimilars. Positive correlations were also observed between intentions towards prescription and beliefs regarding the safety and efficacy of biosimilars. Pharmacists' authority and knowledge of biosimilars correlated with their intention to substitute or dispense them. However, the logistic regression analysis indicated that behavioral, normative, and control beliefs were not significant predictors of the intention to prescribe or substitute biosimilars in either group. <i>Conclusions:</i> Highlighting the significance of continuing education and coordinating efforts in the international harmonization of biosimilar guidelines, as well as education for healthcare professionals, is required for addressing clinical concerns and enhancing confidence in biosimilars.